Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | KCNK2 | O95069 | 11/20 | 0.55 |
| ▸ | KCNK10 | P57789 | 8/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294112 | 0.83 | PLK1 (0.63) | PLK1TRPV1EPHX2NR1H4HDAC2 | |
| SCHEMBL13485813 | 0.83 | TRPV1 (0.58) | TRPV1EPHX2NR1H4KCNK2KCNK10 | |
| SCHEMBL6497472 | 0.81 | TRPV1 (0.56) | TRPV1EPHX2NR1H4KCNK2KCNK10 | |
| SCHEMBL21995806 | 0.81 | TRPV1 (0.56) | TRPV1EPHX2NR1H4KCNK2KCNK10 | |
| SCHEMBL1160810 | 0.79 | HPGD (0.59) | TRPV1EPHX2NR1H4KCNK2KCNK10 | |
| SCHEMBL10919991 | 0.78 | LMNA (0.53) | TRPV1EPHX2NR1H4KCNK2KCNK10 | |
| SCHEMBL25254739 | 0.78 | TRPV1 (0.53) | TRPV1EPHX2NR1H4KCNK2KCNK10 | |
| SCHEMBL16599531 | 0.77 | EPHX2 (0.59) | TRPV1EPHX2NR1H4KCNK2KCNK10 | |
| SCHEMBL250247 | 0.77 | HDAC6 (0.80) | PLK1EPHX2NR1H4HDAC2HDAC8 | |
| SCHEMBL10740573 | 0.76 | ALDH1A1 (0.50) | TRPV1EPHX2NR1H4KCNK2KCNK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362045-B2 | 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8362045-B2 | 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-07 | — | — | US | disclosed |
| WO-2009087285-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ALK, ROS1, CYP11B2 | PLK1 3217/4885TRPV1 749/4885EPHX2 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.